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Abstract
Background: Prevalence of colorectal cancer (CRC) in the British Bangladeshi population (BAN) is low compared to
British Caucasians (CAU). Genetic background may influence mutations and disease features.
Methods: We characterized the clinicopathological features of BAN CRCs and interrogated their genomes using
mutation profiling and high-density single nucleotide polymorphism (SNP) arrays and compared findings to CAU
CRCs.
Results: Age of onset of BAN CRC was significantly lower than for CAU patients (p=3.0 x 10-5) and this difference
was not due to Lynch syndrome or the polyposis syndromes. KRAS mutations in BAN microsatellite stable (MSS)
CRCs were comparatively rare (5.4%) compared to CAU MSS CRCs (25%; p=0.04), which correlates with the high
percentage of mucinous histotype observed (31%) in the BAN samples. No BRAF mutations was seen in our BAN
MSS CRCs (CAU CRCs, 12%; p=0.08). Array data revealed similar patterns of gains (chromosome 7 and 8q), losses
(8p, 17p and 18q) and LOH (4q, 17p and 18q) in BAN and CAU CRCs. A small deletion on chromosome 16p13.2
involving the alternative splicing factor RBFOX1 only was found in significantly more BAN (50%) than CAU CRCs
(15%) cases (p=0.04). Focal deletions targeting the 5’ end of the gene were also identified. Novel RBFOX1 mutations
were found in CRC cell lines and tumours; mRNA and protein expression was reduced in tumours.
Conclusions: KRAS mutations were rare in BAN MSS CRC and a mucinous histotype common. Loss of RBFOX1 may
explain the anomalous splicing activity associated with CRC.
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Background
Colorectal cancer (CRC) is common [1] and most cases
arise sporadically. A small proportion of CRC is associated
with inherited syndromes such as familial adenomatous
polyposis (FAP; <1% of CRC), MUTYH-associated polyp-
osis (MAP; rare recessive condition, carrier estimated
at ~1%) and Lynch syndrome / hereditary non-polyposis
colon cancer (LS/HNPCC; 2-4% of CRC) [1]. FAP patients
have germline mutations in one allele of the adenomatous
polyposis (APC) tumour suppressor gene, MAP patients
carry biallelic mutations in the MUTYH oxidative damage
repair gene and LS is caused by germline mutations in
DNA mismatch repair genes (mostly MLH1 and MSH2,
less commonly MSH6 and PMS2) [1]. Clinically, LS differs
from FAP in that CRC arises without extensive polyposis.
CRC in FAP, MAP and LS are characterised by an early
age of onset (FAP, mean age, 40 years [2,3]; MAP, me-
dian, 45 years (range, 21–67) [4]; LS, median 43 years
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(range, 20–79) [5]). In comparison, sporadic CRC is
rare until the sixth decade [6].
Sporadic CRCs are defined by their dominant genomic
instability pathway and classified into two major groups.
Chromosome unstable CRC (CIN) are characterised by
gross chromosomal abnormalities and present in ap-
proximately 65-70% of CRC [7]. Microsatellite unstable
(MSI) CRCs account for another 15%, and are driven by
defective mismatch repair, which causes increased muta-
tions of short nucleotide repeats (microsatellites) [8].
These two genomic instability pathways are associated
with a difference in prognosis: MSI cancers behave less
aggressively [9]. However, the classification of sporadic
CRCs as CIN or MSI is not always straightforward, as a
significant proportion appears microsatellite and
chromosome stable (MACS) [10,11]. The frequent pres-
ence of epigenomic instability in sporadic CRC in the
form of global hypomethylation or the CpG island methyla-
tor phenotype further complicates the picture [11,12].
Over a third of the population in the borough of
Tower Hamlets, London, United Kingdom (UK) are
Bangladeshi in origin. Interestingly, despite a high
incidence of diabetes mellitus in the BAN population
group [13], prevalence of CRC is lower at 27/100,000
compared to 342/100,000 in the non-Bangladeshi British
population [14]. In an expression array profiling study of a
small cohort of BAN CRCs, Ahmed et al. [14] reported that
the percentage of cases aged less than 40 was high (61%).
The reduced susceptibility to CRC in the BAN popula-
tion and the apparent early age of CRC onset are intri-
guing. Here, we compared the clinicopathological
characteristics of BAN CRC patients presenting to our
local hospital to those from a group of sporadic CAU
CRC patients. We compared molecular genetic profiles
between tumours from these patient groups, including
genome-wide DNA copy number alterations, KRAS and
BRAF mutation to test whether CRCs in the BAN popula-
tion showed molecular features distinct from CAU CRCs.
Results
Clinicopathological features of patients
Between June 1997 and August 2008, all patients with
CRC were invited to participate in research and CRCs
were resected from 44 consented BAN patients at our
centre. BAN CRC patients were recruited sequentially
with patients from the CAU population and there was
no prior selection; no BAN patients were missed during
this time period. The age of CRC onset in the BAN
cohort (median, 58; range, 25–80) was significantly
lower (p=3.0 × 10-5) than for sporadic CAU CRC
patients (median 71; range, 21–91) presenting at the
same hospital. Although the early age of onset could be
partly attributed to a relatively young population [15], it
can also be an indication of a higher prevalence of
inherited CRC syndromes or other predisposing condi-
tions. However, as none of the BAN CRC patients in our
cohort had a history of polyposis or chronic gastrointes-
tinal inflammation when they were diagnosed, it is un-
likely that their cancers are associated with FAP, MAP or
inflammatory bowel disease.
The lower age of onset might reflect a higher preva-
lence of LS. To investigate this, we performed genotyp-
ing with MSI markers BAT25 and BAT26 using DNA
extracted from tumour and matched normal tissue sam-
ples available from 37 patients (age of onset ≤45, n=17;
age of onset >45, n=20; median age, 51). We identified 7
patients (4 early-onset, 3 late-onset) with MSI (all posi-
tive at both the BAT25 and BAT26 loci). In addition,
immunohistochemistry detected loss of one or more
mismatch repair proteins (MLH1, MLH6 or PMS2) in
five of the seven cases (Additional file 1: Table S1). No
tumour showed loss of MSH2. Two of these patients
showed an early-onset of cancer at 40 and 43 years of
age whereas the remaining three were older at diagnosis
(65, 71 and 73). Hence, genetic features suggestive of po-
tential LS cases were detected in 5 out of 37 patients in
our cohort (13.5%), and in 2 out of 17 patients belonging
to the early age group (11.8%). Because family histories
were usually not available from the BAN patients, sup-
porting evidence for a familial predisposition to CRC
could not be obtained. However, additional cancers pre-
sented in two of the five potential LS cases: gastric
adenocarcinoma in one individual and both an adeno-
carcinoma of the lung and endometrial cancer in an-
other (Additional file 1: Table S1). In order to obtain a
more uniform group of sporadic BAN samples for fur-
ther investigation, we excluded all seven patients whose
tumours were MSI and an additional patient (age, 51
years) whose tumour showed loss of PMS2 protein ex-
pression. Importantly, this did not alter the median age
of onset (51.6 vs. 51.4 years). The clinicopathological
data on these BAN patients with sporadic MSS stable
cancers are summarised in Table 1.
Subsequent comparisons focused on the remaining 29
BAN MSS patients with presence of mismatch repair
protein expression: 13 patients diagnosed under the age
of 45 were classified as early-onset (median, 34; range,
25–45), while the remaining 16 patients diagnosed over
the age of 45 (median, 64; range, 51–80) were classified
as late-onset. Overall, BAN MSS cancers were frequently
left-sided (79.3%) and more prevalent in males (65.5%).
Most of the cancers were moderately differentiated
(82.8%). There was a high percentage of mucinous
tumours (31%) compared to the background CAU popu-
lation (5-15%) [16]. Within the BAN MSS group,
left-sided location was significantly more prevalent in
early-onset (13/13, 100%) than in late-onset cancers (10/16,
63%) (p=0.02, Fisher’s Exact Test) (Table 1). However,
Sengupta et al. Molecular Cancer 2013, 12:1 Page 2 of 11
http://www.molecular-cancer.com/content/12/1/1
early-onset and late-onset BAN MSS cancers had
similar male: female ratios and showed no difference
in stage, prevalence of mucinous phenotype, frequency
of vascular invasion, degree of differentiation or resec-
tion (R) status (Table 1).
Sequence analysis of KRAS and BRAF mutation hotspots
We compared the mutation frequencies of KRAS and
BRAF between BAN CRC and CAU CRCs by perform-
ing sequence analysis of known mutation hotspots
(codon 12 and 13 for KRAS and codon 600 for BRAF).
In the BAN MSS samples (n=29) we found two muta-
tions at codon 12 of KRAS (2/29, 5.4%), one in an early-
onset and another in a late-onset CRC. This mutation
rate is lower than in our previously characterised CAU
MSS CRCs (KRAS, 33/134, 25%) [11], and the
differences between populations were significant (p=0.04).
Interestingly, the presence of KRAS mutations has been
associated with a non-mucinous histotype [17]. The low
prevalence of KRAS mutations in our BAN MSS samples
may be correlated to the high percentage of mucinous
tumour observed (30% in BAN MSS samples with wildtype
KRAS). No mutations were observed in the BRAF gene in
BAN. Although a lower frequency of BRAF mutation is
expected for MSS CRCs, this frequency is still lower than
that observed in our CAU MSS sample set (17/144, 12%).
Genomewide copy number analysis using single
nucleotide polymorphism (SNP) beadarray
The pattern of somatic genomic copy number alterations
in BAN and CAU CRCs was evaluated using SNP arrays.
DNA was obtained from ten matched tumour-normal
Table 1 Clinical and pathological characteristics of the BAN MSS colorectal cancers
Overall Early onset (≤45 years) Late onset (>45 years) P value
(n = 29) (n = 13) (n = 16) (Early Vs Late)
Age of Onset - Yr
Median 57 35 64 -
Range 25-80 25-45 51-80
Sex – No (%)
Female 10 (34.5) 5 (38.5) 5 (31.3) N.S.
Male 19 (65.5) 8 (61.5) 11 (68.7)
Site of Cancer – No (%)
Right 6 (20.7) 0 (0) 6 (38.5) 0.021
Left 23 (79.3) 13 (100) 10 (62.5)
Dukes’ Stage – No (%)
A 3 (10.3) 1 (7.7) 2 (12.5) N.S.
B 6 (20.7) 2 (15.4) 4 (25)
C 19 (65.5) 10 (76.9) 9 (56.2)
D 1 (3.4) 0 (0) 1 (6.3)
Mucin - No (%)
No 20 (69.0) 7 (53.8) 13 (81.2) N.S.
Yes 9 (31.0) 6 (46.2) 3 (18.8)
Vascular Invasion - No (%)
No 16 (55.2) 8 (61.5) 8 (50) N.S.
Yes 13 (44.8) 5 (38.5) 8 (50)
Differentiation - No (%)
Well 1 (3.4) 1 (7.7) 0 (0) N.S.
Moderate 24 (82.8) 10 (76.9) 14 (87.5)
Poor 4 (13.8) 2 (15.4) 2 (12.5)
Resection Status - No (%)
0 21 (72.4) 10 (76.9) 11 (68.7) N.S.
1 7 (24.1) 3 (23.1) 4 (25)
2 1 (3.4) 0 (0) 1 (6.3)
All p values were calculated using Fisher’s Exact Test (two-tailed) and p ≤ 0.05 was considered to be significant.
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pairs from the BAN MSS patient group (early-onset,
n=4; late-onset, n=6), where fresh frozen tissues were
available. For comparison, we extracted DNA from
paired tumour and normal tissues from a group of MSS
CRC from the CAU population (n=27). We had previ-
ously classified these samples as CIN (n=11) and MACS
(n=16) CRCs, using flow cytometry ploidy analysis and
loss of heterozgosity (LOH) markers specific to chromo-
some instability [11].
In total, 37-paired CRC samples were hybridised onto
Illumina bead arrays (BAN, n=10, Hap550 bead arrays;
CIN, n=11, and MACS, n=16, HumanHap370- Duo bead
arrays) and analysed using OncoSNP [18]. The use of
high-density SNP array allowed a wide range of genomic
alterations to be determined, including small amplifica-
tions, small deletions, and copy number neutral loss of
heterozygosity (2nLOH) events. All tumour samples
contained genomic alterations. To obtain an overview of
the genetic complexity of the samples using SNP array
data, we determined: (i) the average ploidy of the sam-
ple, by taking the average copy number over all SNPs;
(ii) the percentage of the genome altered, by taking the
fraction of SNPs showing somatic differences compared
to the matched normal. In order to support our analysis,
we also used genome-wide SNP genotyping data from
an additional dataset generated from 636 CRC samples
to provide a background for visualisation.
The cancer samples fell into three broad, distinct clus-
ters (Figure 1). The first was a diploid group (average
ploidy=2) of cancers with a minimal number of genomic
aberrations (<10%). This group contained seven of the
sixteen MACS samples (44%) and one of the four early-
onset cancers (25%) from the BAN cohort. By definition,
we would not expect any CIN cancers to be associated
with this group, and our SNP genotyping data supported
this. The second was the set of chromosomally unstable
cancers (>50% genome altered) exhibiting polyploidy
(average ploidy >3). As expected, the majority of the
CIN cancers, as defined by earlier ploidy analysis (82%,
9/11), was located in this group, and was accompanied
by a single MACS (6%) CRC. Also in this set were two
early-onset (50%) and four late-onset BAN cancers
(67%). A third intermediate group (Figure 1) had an
average ploidy >2 and moderate levels of genomic aber-
rations (10-50%). Within this group there was a concen-
tration of MACS cancers (50%, 8/16) and early- (25%,
1/4) and late-onset (33%, 2/6) BAN MSS cancers along
with a small number of CAU CIN CRCs (18%, 2/11)
Genome-wide permutation testing was used to assess
if any SNPs were significant markers for differentiating
Figure 1 The distribution of genomic complexity for (C)IN, MAC(S), (E)arly and (L)ate-onset colorectal cancer. Data for 636 samples (grey)
from the Ludwig Colon Cancer Initiative data set was used as background reference. (Inset) Expanded view showing clustering of samples with
few genomic aberrations.
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between early- and late-onset BAN cancers. In our sam-
ple set, no individual marker or set of markers had any
stratification effect (p >0.001).
Chromosomal regions frequently altered in Bangladeshi
and Caucasian colorectal cancers
In terms of absolute copy number change (Figure 2A, in
blue), the most frequently observed gene amplifications
in the BAN CRC samples were located on chromosomes
7, 8q and 17q. This pattern overlaps with CAU MSS
cancers where amplification in CIN CRCs are mostly
observed on chromosomes 2q, 5p, 7p, 13, 17q and 20q,
and in MACS cancers on chromosomes 7, 8q and 20q
(Figure 2A). After eliminating amplification due to
increased ploidy, the relative copy number gains in the
BAN samples remained on chromosomes 7 and 8q
(Figure 2B). Absolute copy number loss (Figure 2A, in red)
was relatively rare compared to gains, with the most notice-
able losses in the BAN CRCs located on chromosome 8p.
A different picture emerged when deletions relative to
average ploidy were analysed (Figure 2B, in red), and
regions of frequent relative loss in BAN samples included
chromosomes 8p, 17p and 18q (8/10, 80%). These results,
again, showed similarities with the alterations detected typ-
ically in the CIN and MACS CAU cancers, although few
regions of loss were detected in MACs samples (Figure 2B).
In the BAN samples, LOH was not observed as frequently
as amplification and deletions (Figure 2C), and the regions
with the highest frequency of LOH were located on 4q, 17p
and 18q (5/10, 50%). The pattern of LOH in BAN samples
Figure 2 Genome-wide copy number profiles. (A) Genome-wide absolute copy number profiles for the four classes of colorectal cancers. Blue
– Copy number gain (>2). Red – Copy number loss (<2). (B) Genome-wide relative (to average ploidy) copy number profiles. Blue – relative gain,
Red – relative loss. (C) Genome-wide LOH profiles..
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was again similar to that observed in the CIN and MACS
sporadic cancers, where LOH was observed repeatedly on
chromosomes 17p (13/27, 48%) and 18q (15/27, 55%).
In total, over 45% of our cases showed deletions and/or
LOH at chromosome 17p (BAN: 5/10, 50%; CIN: 5/11,
45%; MACS: 7/16, 44%). The genomic regions altered in
most cases were large, encompassing the majority of the
short arm of chromosome 17. Importantly, almost all of
these alterations involve LOH or allelic deletion at the
TP53 locus (17p13.1) (BAN, 4/5, 80%; CIN, 5/5, 100%;
MACS, 6/7, 86%). Loss of TP53 is a consistent feature
across the BAN, CIN and MACS CRCs and is therefore
likely to be the major factor influencing tumour
development at this locus. A similar situation was observed
on chromosome 18q, where SMAD4 (18q21.2) was lost in
six BAN samples (6/10; 60%) six CIN samples (6/11, 55%)
and three MACS samples (3/16; 19%). In comparison, gross
chromosomal alterations at the APC locus (5q22.2) were
less frequent in all subgroups of samples (BAN, 3/10, 30%;
CIN, 4/11, 36%; MACS, 3/16, 19%).
A small deletion on chromosome 16p13.2, containing the
RBFOX1 gene, was detected in both Bangladeshi and
Caucasian CRCs
Interestingly, we detected a small deletion on chromosome
16p13.2 from 6.0 to 7.7 Mb in ten samples (Figure 3A),
Figure 3 Genomic alterations and expression changes of RBFOX1 in CRC. (A) Analysis of relative copy number (blue) gain and (red) loss
across all cancers (CIN, MACS and BAN) shows recurrent deletions on chromosome 16p13 affecting the RBFOX1 gene. (B) Scatter plot showing
RBFOX1 gene expression level as detected by quantitative real time PCR. Nineteen tumour / normal sample pairs were tested and mRNA level is
expressed as ratio of RBFOX1 and HPRT concentration, [RBFOX1] / [HPRT].
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including five BAN (5/10, 50%), 2 from early-onset and 3
from late-onset, three CIN (3/11, 27%) and one MACS
(1/16, 6%). Accordingly, this deletion might be more fre-
quent in BAN CRCs than CAU CRCs (5/10 versus 4/27;
p=0.04, Fisher’s Exact Test). According to the University of
California Santa Cruz (UCSC) Genome Bioinformatics
database (http://genome.ucsc.edu/), this genomic region
contains only one known gene, RNA binding protein, fox-1
homolog (RBFOX1). Deletion of RBFOX1 has been
detected in 35% of MSI and 21% of MSS colon tumours in
a previous study, and fluorescence in situ hybridization was
performed to confirm the somatic deletion of this locus in
four samples [19]. Deletion of RBFOX1 was also presented
in a significant proportion of CRC (106/419) in The Cancer
Genome Atlas dataset [20] (Additional file 2: Figure S1).
The deletion clusters included hemizygous loss of the entire
gene and more focal deletions primarily targeting the regu-
latory and 5’ exons of RBFOX1.
RBFOX1 is an RNA binding protein, which has a role
in splicing regulation, and the gene is transcribed into a
few alternatively spliced isoforms [21,22]. Although
RBFOX1 is highly expressed in the nucleus and / or
cytoplasm in the brain, heart and skeletal muscle, its ex-
pression in the intestines has not been defined clearly.
Therefore, we sought evidence of RBFOX1 expression by
quantitative real time PCR (QRT-PCR) using cDNA
from 43 colorectal cell lines and 19 paired CAU CRC
tumour/normal tissues, where good quality RNA was
available. In most cell lines (36/43, 84%), the threshold
cycle (Ct) values produced in the QRT-PCR experiment
indicated absence or undetectable levels of RBFOX1
mRNA transcript, whereas low level of RBFOX1 mRNA
was found in the remaining seven cell lines (Ct range:
33.1-33.8) (Additional file 3: Table S2). In contrast,
RBFOX1 mRNA was detected in all normal tissues sam-
ples (Ct range: 23.6-36.7, median, 31.6). Furthermore, in
most tumour samples the expression level of RBFOX1
was reduced compared to the normal paired tissue sam-
ples (Figure 3B, Additional file 3: Table S2). As RBFOX1
appears to be expressed at low level, the possibility that
Figure 4 Immunohistochemical detection of RBFOX1. (A) Normal appearing colonic mucosa with diffuse cytoplasmic staining of most
epithelium (x100). (B) Normal colon with diffuse staining of the epithelium and some stromal cells and inflammatory cells; the pericryptal sheath
fibroblasts appear unstained (x200). (C) Adenocarcinoma showing absence of RBFOX1 staining in the majority of the cells lining the two-
neoplastic glands in the lower half of the picture (x200). (D) Neighbouring glands show persistence (left) or reduction/ loss (right) of RBFOX1
immunoreactivity on epithelial cell cytoplasm (x200).
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its expression is restricted to particular cell types was
considered. The immunohistochemical expression of
RBFOX1 in human non-neoplastic colon and colon can-
cer tissues was assessed (Figure 4). Staining was detected
in the cytoplasm of normal colonic epithelium and
reduced levels of RBFOX1 expression were observed in
the some of the tumour samples we tested (Figure 4C).
To assess the mutation frequency of RBFOX1 in
CRC, we performed high-resolution melt (HRM)
analysis on 39 CRC cell lines and 137 tumour and
normal samples. All changes were then confirmed by
bidirectional Sanger sequencing. In total, we found
six novel mutations in five cell lines, (5/39, 12.8%)
and three novel mutations in two tumour/normal
samples pairs (2/133, 1.5%) (Table 2, Additional file 4:
Table S3). The somatic mutations were further ana-
lyzed for the potential or likely effect of amino acid
substitutions on protein structure and function,
using Sorts Intolerant From Tolerant (SIFT) and
Polymorphism Phenotyping (PolyPhen-2) (Additional
file 4: Table S3). Of the nine novel mutations, two
were predicted to be possibly damaging/deleterious
by SIFT and PolyPhen-2, two were silent mutations
and the remaining five produced contradictory pre-
dictions by SIFT and PolyPhen-2. Further investiga-
tions will be required to understand the functional
effects of these somatic mutations on RBFOX1 func-
tion and CRC.
Discussions
Very little research has been done to characterise CRCs
arising in Bangladeshi patients, despite the reportedly
low frequency of CRC and suggestions of a high propor-
tion of early-onset CRCs in this population [14]. Here
we confirmed that BAN patients have a relatively early
age of onset of CRC compared to CAU patients present-
ing at the same hospital and that the age of onset
remains low even after potential LS cases have been
omitted. This raises the possibility that BAN CRCs have
arisen as a result of environmental influences and/or a
genetic predisposition that can lead to somatic molecu-
lar changes and clinicopathological features dissimilar to
those found in tumours from the wider UK population.
This study aimed to uncover any clinical or genetic fea-
tures specific to BAN CRCs.
We observed no major differences in the clinical fea-
tures between early- and late-onset BAN MSS, and most
findings were consistent with CAU MSS cancers
reported previously [11]. Survival of the early-onset and
the late-onset BAN MSS CRC was similar, even though
the early-onset cases were all left-sided unlike the late-
onset (62.5% left-sided). We cannot, however, rule out a
relationship between age of onset and survival as our co-
hort was relatively small. It also remains to be seen if
BAN CRC characteristics change over time and between
generations, particularly as environmental factors such
as diet change can impact on the population.
There were, however, an unexpectedly large propor-
tion of mucinous tumours in the BAN sample set. This
observation may be linked to the reduced frequency of
KRAS mutations in BAN MSS compared with CAU
CRCs and CRCs in other populations. Specifically, KRAS
is mutated at frequencies between 30%-44% in African
American, Chinese and Japanese CRCs [23-25]. It is dif-
ficult to ascertain if the high proportion of early-onset
cases causes the reduction in the number of KRAS
mutations in BAN, as previous studies suggested only
marginal differences between early-onset and late-onset
CAU CRCs with regard to KRAS mutations (<50 years,
29%; >50 Years, 33%) [26]. These frequencies also con-
cur with those we reported previously for CAU CRCs
[11]. On the other hand, there is evidence that KRAS
mutation frequency is lower in early-onset CRC in India
(≤50 years, 24%; ≥60 Years, 47%) [27]. Further investigation
in BAN CRCs will help to explain the aetiology behind the
low KRAS mutations and high mucin percentage.
We found no BRAF mutations in BAN MSS CRC,
although the absence of MSI cancers in the cohort may
contribute to this observation [28]. Overall, it will be
interesting to confirm these results in a larger cohort of
BAN patients and establish how this may affect clinical
decision, particularly in view of the increased use of tar-
geted therapy in CRC.
Table 2 RBFOX1 mutations and single nucleotide
polymorphisms found in CRC cell lines and patient
tumour samples
Mutations Known SNPs
Cell Lines
CoCM1 c.776C>T; p.Ser259Phe
HCT15 c.288C>T; p.Ser96Ser
LIM2405 c.393A>G; p.Glu131Glu (rs140174146)
LIM2551 c.154delC
LOVO 1. c.293C>T; p.Ala98Val
2. c.353C>T; p.
Thr118Met
LS411 c.293C>T; p.Ala98Val
Patient Samples
33 1. c.851C>T; p.
Ala284Val
2. c.1023G>A;
p.Gln341Gln
53 c.350C>T; p.Pro117Leu*
93 c.598G>A; p.Val200Met
*Mutation from patient 53 is identical to known SNP rs139251660, but was
present only in tumour but not in the paired normal tissue.
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We utilised high-density SNP bead arrays to detect
any genomic alterations that might be specific to BAN
patients. The BAN cohort contained both diploid and
polyploid cancers, and the copy number changes
detected were largely comparable to those seen in the
CAU CRCs. We also identified small, heterozygous dele-
tions on chromosome 16p13.2 in a substantial number
of BAN and CAU MSS CRCs. Deletion of this part of
the genome has been previously described in a number
of studies on genomic alterations in CAU and Japanese
CRCs [29-33].
In our sample set, the deletion was more frequent in
BAN CRCs compared to CAU cancers, although there
was no difference in occurrence between early- and late-
onset BAN CRCs. This region of the genome encodes
RBFOX1, a highly conserved RNA-binding protein that
regulates tissue-specific alternative splicing indicating
important basic functions in development and differenti-
ation. When we examined RBFOX1 in a large number of
CRCs from The Cancer Genome Atlas Network sample
set, we found that the regulatory regions and 5’ exons of
the gene is often deleted, which may lead to aberrant
RBFOX1 expression or isoform distribution. Interestingly,
in a recent study the 5’ untranslated region of RBFOX1 was
also rearranged in 4/25 melanoma [34], pointing to the
possible importance of this part of the gene.
Very little is known about the expression or role of
RBFOX1 in the intestine. Using immunohistochemistry,
we confirmed that RBFOX1 is expressed at low levels in
normal gut tissues and that expression is often lost in
CRC. We also identified a small number of novel somatic
mutations in CRC. Therefore, RBFOX1 appears to be tar-
geted by various mechanisms in CRC. Functionally, loss of
RBFOX1 activity may lead to aberrations in the splicing of
a significant number of genes, generating diverse functional
products that vary from those found in normal tissue [35].
Alternative splicing is a key feature of cancer [36-38] in-
cluding CRC [35,39] and the identification of RBFOX1 tar-
gets in CRC will help to determine if RBFOX1 deletion is a
critical feature of dysfunctional splicing in CRC.
To our knowledge, this is the first report of genomic
characterisation of CRC in British Bangladeshi popula-
tions. We concluded that there were no genetic copy
number alterations unique to BAN MSS CRCs, but that
mutations of RAS signalling oncogenes were compara-
tively rare. The functional role of RBFOX1 mutations in
BAN and CAU MSS CRC highlights aberrant alternative
splicing in CRC as an important mechanism for further
study.
Materials and methods
Patients and tumour samples
CRCs were resected from 44 patients of Bangladeshi ori-
gin at Barts and the London NHS Trust between January
1997 and August 2008. Tumour tissue (fresh frozen or
formalin fixed paraffin embedded) was obtained from 37
patients. Within this group, 17 (46%) were 45 years old
or under at the time of diagnosis.
Fresh-frozen tumor and matched normal tissues were
retrieved from 133 stage II and III CRC patients treated
at the Royal Melbourne Hospital and Western Hospital
Footscray, Australia. A total of 67 individuals were
female and 66 were male, with a median age at diagnosis
of 73 years (range, 30–92 years). 89 cancers were stage II
and 44 were stage III. 57 cancers were from the proximal
colon, 64 from the distal colon and 12 from the rectum.
Microsatellite instability genotyping and
immunohistochemistry of mismatch repair protein
For microsatellite instability assay, DNA was extracted from
tumour tissues using QIAamp DNA mini kit (Qiagen,
Hilden, Germany) and genotyping was performed using
BAT25 and BAT26 mononucleotide markers [40] on the
ABI 3100 DNA Sequencer (Applied Biosystems) and ana-
lysed using GeneScan software (Applied Biosystems). For
fresh frozen tumour tissues, only samples with >80%
tumour were used in experiments, and FFPE tumour tis-
sues were macrodissected before DNA extraction. Tumours
were classified as microsatellite unstable if one or more of
the markers showed bandshift of 3 base pairs or more. The
expression of the mismatch repair proteins was assessed
using immunohistochemistry (IHC) [41].
Statistical analysis
GraphPad Prism version 4.03 for Windows (GraphPad
Software, San Diego, California, USA) was used for stat-
istical analysis.
Single nucleotide polymorphism beadarrays and data
analysis
Single nucleotide polymorphism (SNP) genotyping of
Bangladeshi and Caucasian MSS CRCs was performed
using the HumanHap 550 Duo and 370 Duo BeadChip
(Illumina) respectively, after confirmation of DNA
quality using Agilent biochips. For comparison, we also
utilised Ilumina 610-Quad SNP genotyping data from
636 cancers obtained from the Ludwig Colon Cancer
Initiative, Australia.
For copy number analysis, SNP data for the tumour
samples were pre-processed by regressing Log R Ratio
values for the tumour against corresponding values for
the paired normal to reduce the effect of array artefacts.
The SNP data was then examined for copy number and
LOH changes in paired tumour/normal tissue using
OncoSNP (version 2.25) [PMID: PMC2965384]. We
used the intra-tumour heterogeneity option with 10 EM
iterations and sub-sampling window size of 30. Two
early-onset BAN and 4 CIN samples were excluded on
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the basis of poor data quality. For comparisons, copy
number and LOH calls from the Illumina Human
Hap500 and 610-Quad SNP genotyping data were re-
mapped using nearest neighbour interpolation on to the
HumanHap370-Duo probe set. FOXRB1 deletions were
further investigated in a dataset of 419 colorectal cancers
from The Cancer Genome Atlas Project. Affymetrix
SNP 6.0 CEL files were preprocessed and converted into
the OncoSNP (v1.3) format using the PennCNV-Affy
tool [PMID: PMC2045149]. Colorectal tumours showing
RBFOX1 deletions were identified and then clustered
using a k-means algorithm. Genomic coordinates are in
Human Genome Build hg18.
Mutation analysis
Mutation hotspots in KRAS and BRAF were analysed by
direct sequencing (Life Technologies). RBFOX1 exons
were screened using high resolution melt curve analysis
on xthe ABI 7500 Fast Real Time PCR system (Life
Technologies) and analysed using the HRMv2.0.1 software
(Life Technologies). Somatic mutations were then validated
by bidirectional Sanger sequencing twice and confirmed to
be absent in paired normal tissues. Primer sequences are
available from authors. Mutations were analysed for the ef-
fect of amino acid substitutions on protein structure and
function, using Sorts Intolerant From Tolerant (SIFT) at
http://sift.bii.a-star.edu.sg/ and Polymorphism Phenotyping
(PolyPhen-2) at http://coot.embl.de/PolyPhen/.
Quantitative real time PCR and immunohistochemistry on
RBFOX1
Quantitative Real-time polymerase chain reaction (QPCR)
was performed using TaqMan assays (Applied Biosystems)
against RBFOX1 (Hs00251554_m1) and thecontrol house-
keeping gene HPRT (hypoxanthine phosphoribosyltransfer-
ase 1;HuHPRT_0604009). Immunohistochemistry was
carried out using rabbit polyclonal primary antibody against
RBFOX1 (sc-135476, Santa Cruz Biotechnology).
Ethics approval
Ethical approval for this study was obtained from the
Human Research Ethics Committees of all sites and all
patients gave informed consent.
Additional files
Additional file 1: Table S1. Loss of mismatch repair proteins MLH1,
MLH6 and PMS2 in a subset of British Bangladeshis colorectal cancers. No
tumour showed loss of MSH2.
Additional file 2: Figure S1. UCSC Genome Browser showing
hemizygous deletions/LOH (Red) and homozygous deletions (Yellow) of
RBFOX1 in The Cancer Genome Atlas colorectal adenocarcinoma sample
set. Deletions are typically hemizygous loss of the entire gene and focal
deletions primarily targeting 5’ end of the gene.
Additional file 3: Table S2. RBFOX1 mRNA expression in CRC cell lines
and paired CRC and normal tissues samples.
Additional file 4: Table S3. Somatic mutations and single nucleotide
polymorphisms found in CRC cell lines and paired CRC and normal
tissues samples.
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